XPhyto adds Top-Level Executive Talent to its Global Operations
Apr 20, 2021
XPhyto announces the appointment of Mr. Wolfgang Probst as the Chief Operations Officer (COO) of XPhyto and the addition of Mr. Manfred Buchberger as the...
XPhyto announces European Approval for 25 Minute COVID-19 PCR Test
Mar 18, 2021
CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2Rapid results with ease of use - single 20-minute PCR cycle plus...
XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test
Mar 10, 2021
Vancouver, Canada (March 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...
XPhyto Completes Corporate Rebranding and Launches New Website
Mar 4, 2021
Vancouver, Canada (March 4, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...
Xphyto provides updated comments on promotional and marketing activity
Feb 26, 2021
VANCOUVER, British Columbia – February 26, 2021 – XPhyto Therapeutics Corp. (CSE: XPHY; OTC: XPHYF; FSE: 4XT) (“XPhyto” or the “Company”) at the request of...
XPhyto Places First Order For 25-Minute COVID-19 RT-PCR Tests
Feb 24, 2021
Vancouver, Canada (February 24, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that it has...
XPhyto Builds Commercial Team To Launch 25-Minute COVID-19 RT-PCR Test
Feb 22, 2021
Vancouver, Canada (February 22, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...
XPhyto European CE-IVD Application For 25-Minute COVID-19 RT-PCR Test
Feb 16, 2021
Vancouver, Canada (February 16, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...
XPhyto Adds Mescaline Production To Psychedelic Medicine Programs
Feb 10, 2021
Vancouver, Canada (February 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...
XPhyto Announces Psychedelic Pharmaceutical Production Agreement
Feb 3, 2021
Vancouver, Canada (February 3, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that XPhyto Laboratories...
XPhyto Announces Drug Formulation Strategy And 2021 Milestones
Jan 28, 2021
Construction of commercial drug manufacturing facility in GermanyFour clinical studies in neurological indications in 2021Development of oral biosensor and contract development & manufacturingPsychedelic transdermal and...
XPhyto Announces Business Strategy And Milestones For 2021
Jan 18, 2021
Commercialization of rapid COVID-19 PCR testClinical validation of transdermal and sublingual drug formulationsPsychedelic API production, drug formulation and clinical integration Vancouver, Canada (January 18, 2021)...
